Basis: FMP quote price / unrounded diluted EPS from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/E ratio is N/A as of 2026-10-06T14:11:39.141Z.
Calculation as of: 2026-10-06T14:11:39.141Z.
Quote observation: 2026-10-06T14:10:24.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 6dae1ed753b385efcb651dd8f32a10b6f9886011747f410ddce9f57bee9a14c9
PE RATIO
N/A
Market Cap
$4.69B
PE Ratio
93.24
TTM Avg
202.48
3Y Avg
202.48
5Y Avg
202.48
Market Cap
$4.58B
PE Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$5.13B
PE Ratio
35.47
TTM Avg
36.67
3Y Avg
43.17
5Y Avg
53.01
| NAME | MARKET CAP | PE RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Dianthus Therapeutics, Inc. (DNTH) | $4.71B | N/A | N/A | N/A | N/A |
| Mirum Pharmaceuticals, Inc. (MIRM)vs › | $4.82B | N/A | N/A | N/A | N/A |
| Definium Therapeutics, Inc. (DFTX)vs › | $4.66B | N/A | N/A | N/A | N/A |
| LifeStance Health Group, Inc. (LFST)vs › | $4.69B | 93.24 | 202.48 | 202.48 | 202.48 |
| BillionToOne, Inc. (BLLN)vs › | $4.91B | 172.07 | 879.32 | 879.32 | 879.32 |
| Erasca, Inc. (ERAS)vs › | $4.93B | N/A | N/A | N/A | N/A |
| Adaptive Biotechnologies Corporation (ADPT)vs › | $4.58B | N/A | N/A | N/A | N/A |
| Scholar Rock Holding Corporation (SRRK)vs › | $5.04B | N/A | N/A | N/A | N/A |
| Merit Medical Systems, Inc. (MMSI)vs › | $5.13B | 35.47 | 36.67 | 43.17 | 53.01 |
| Cogent Biosciences, Inc. (COGT)vs › | $5.16B | N/A | N/A | N/A | N/A |
Trailing P/E
N/A
Forward P/E
N/A
Forward P/E is calculated using analyst consensus EPS estimates for the current or next fiscal year.
Calculation:
Current Price
$84.20
Forward EPS (Est.)
$-3.79
Forward P/E
N/A
Source: FMP Analyst Consensus Estimates. Forward EPS represents the average analyst estimate for the nearest fiscal year.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
